Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2022-502113-28-00 | Other Identifier | EUCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma. Follicular lymphoma is a type of non-Hodgkin lymphoma or NHL. Participants with follicular lymphoma that has come back after treatment (called "relapsed") or did not respond to treatment (called "refractory") are eligible to take part only in Part 1A of the study.
This study is made up of 3 parts: Part 1A (non-randomized), Part 1B and Part 2 (randomized - controlled).
The aim of Part 1A and Part 1B of the study is to see how safe and tolerable the study drug in combination with chemotherapy is and to determine the dose and schedule of the study drug to be combined with chemotherapy to be used in Part 2 of the study.
The aim of Part 2 of the study is to assess how effective the combination of the study drug with chemotherapy is in comparison with the combination of rituximab and chemotherapy (the current standard-of-care for NHL). Standard-of-care means the usual medication expected and used when receiving treatment for a condition.
The study is looking at several other research questions, including:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Odronextamab + Chemotherapy | Experimental | Part 1 of the study includes ordonextamab dose escalation for participants with previously untreated FL and relapsed/refractory FL (Part 1A only) followed by a randomized exploration of 2 regimens of odronextamab (Odro) and cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) with the objective of dose optimization (Part 1B) in previously untreated patients with FL. |
|
| Rituximab + Chemotherapy | Active Comparator | In Part 2 only, participants will be randomized 1:1:1 to receive rituximab (R) with chemotherapy (CHOP), followed by rituximab monotherapy maintenance. |
|
| Odronextamab + Chemotherapy + Maintenance | Experimental | In Part 2, participants will be randomized 1:1:1 to receive odronextamab with chemotherapy [CHOP, or cyclophosphamide, vincristine, and prednisone (CVP)], followed by odronextamab monotherapy maintenance. |
|
| Odronextamab + Chemotherapy + No maintenance | Experimental | In Part 2, participants will be randomized 1:1:1 to receive odronextamab with chemotherapy (CHOP, or CVP) without maintenance. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Odronextamab | Drug | Administered by intravenous (IV) infusion |
|
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of dose limiting toxicities (DLTs) for odronextamab in combination with chemotherapy | Part 1, DLT period | Up to 35 days |
| Incidence of treatment-emergent adverse events (TEAEs) of odronextamab in combination with chemotherapy | Part 1, Treatment period | Up to 2 years |
| Severity of TEAEs of odronextamab in combination with chemotherapy | Part 1, Treatment period | Up to 2 years |
| Complete Response rate at 30 months (CR30) assessed by independent central review (ICR) | Part 2 | Up to 30 months |
| Measure | Description | Time Frame |
|---|---|---|
| Odronextamab concentrations in serum when administered with chemotherapy | Part 1, Maintenance period and Part 2, Induction period | Up to 30 months |
| Odronextamab concentrations in serum when administered as monotherapy |
Not provided
Key Inclusion Criteria:
Have diagnosis of cluster of differentiation 20 positive (CD20+) FL grade 1-3a, stage II bulky or stage III / IV
Have measurable disease on cross sectional imaging documented by diagnostic computed tomography [CT], or magnetic resonance imaging [MRI] imaging, as described in the protocol
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Adequate bone marrow and hepatic function.
Key Exclusion Criteria:
Note: Other protocol-defined Inclusion/Exclusion criteria apply
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Trial Management | Regeneron Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Boca Raton Clinical Research (BRCR) Global | Plantation | Florida | 33322 | United States | ||
| Investigative Clinical Research of Indiana |
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
When Regeneron has:
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Rituximab | Drug | Administered by IV infusion, or subcutaneous (SC) |
|
|
| Cyclophosphamide | Drug | Administered by IV infusion |
|
|
| Doxorubicin | Drug | Administered by IV infusion |
|
|
| Vincristine | Drug | Administered by IV infusion |
|
|
| Prednisone/Prenisolone | Drug | Administered orally (PO) |
|
|
Part 1 and Part 2, Maintenance period
| Up to 30 months |
| Incidence of anti-odronextamab antibodies (ADAs) | Part 1 and Part 2 | Up to 30 months |
| Titers of ADAs to odronextamab | Part 1 and Part 2 | Up to 30 months |
| Incidence of neutralizing antibodies (NAb) to odronextamab | Part 1 and Part 2 | Up to 30 months |
| Best overall response (BOR) as assessed by the investigator | Part 1, end of Induction period and end of Maintenance period | Up to 30 months |
| Progression free survival (PFS) as assessed by ICR | Part 2 | Up to 5 years |
| CR30 as assessed by local investigator | Part 2 | Up to 30 months |
| Change in patient reported physical functioning scale scores on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Cancer-30 (EORTC-QLQ-C30) | Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a global health status (GHS)/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden. | Up to 5 years |
| PFS as assessed by local investigator | Part 2 | Up to 5 years |
| Event-free survival (EFS) as assessed by ICR | Part 2 | Up to 5 years |
| EFS as assessed by local investigator | Part 2 | Up to 5 years |
| Overall Survival (OS) | Part 2 | Up to 5 years |
| BOR as assessed by local investigator | Part 2 | Up to 30 months |
| BOR as assessed by ICR | Part 2 | Up to 30 months |
| Duration of response (DOR) assessed by ICR | Part 2 | Up to 5 years |
| DOR as assessed by local investigator | Part 2 | Up to 5 years |
| Time to next anti-lymphoma treatment (TTNT) | Part 2 | Up to 5 years |
| Incidence of TEAEs | Part 2 | Up to 2 years |
| Severity of TEAEs | Part 2 | Up to 2 years |
| Change in patient reported health related quality of life (HRQoL) as measured by EORTC-QLQ-C30 | Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden. | Up to 5 years |
| Change in cancer disease as measured by EORTC-QLQ-C30 | Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden. | Up to 5 years |
| Change in treatment related symptoms as measured by EORTC-QLQ-C30 | Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden. | Up to 5 years |
| Change in patient-reported lymphoma disease as measured by the Lymphoma Subscale of the Functional Assessment of Cancer Treatment-Lymphoma (FACT-LymS) | Part 2 The FACT-Lym lymphoma subscale (LymS) includes 15 items to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). Higher scores are associated with a worse quality of life. | Up to 5 years |
| Change in treatment-related symptoms as measured by the FACT-LymS | Part 2 The FACT-LymS includes 15 items to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). Higher scores are associated with a worse quality of life. | Up to 5 years |
| Change in patient-reported general health status per EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) | Part 2 The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: "no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems". The EQ VAS records the participant's self-rated health on a vertical visual analogue scale where the endpoints are labeled "Best imaginable health state" and "Worst imaginable health state". | Up to 5 years |
| Change in patient-reported treatment side effects burden per Functional Assessment of Cancer Therapy-General Global Population Item 5 (FACT-G GP5) | Part 2 A single item GP5 of the validated FACT-G questionnaire will be used to assess from the participant perspective the overall impact of treatment side-effect. The question item is on a 5-point scale ranging from "not at all" (0) to "very much" (4). | Up to 5 years |
| Change in Patient Global Impression of Severity (PGIS) | Part 2 The PGIS includes a single-item to assess how a patient perceives the overall severity of cancer symptoms over the past 7 days. Patients will choose the response that best describes the severity of their overall cancer symptoms with options on a 5-point scale ranging from 1 (No symptoms) to 4 (Very Severe). | Up to 5 years |
| Change in Patient Global Impression of Change (PGIC) | Part 2 The PGIC item includes a single-item to assess how a patient perceives their overall change in health status since the start of study treatment. Patients will choose from response options on a 7-point scale ranging from 1 (Much Better) to 7 (Much worse); 1- Much Better, 2-Moderately Better, 3-A Little Better, 4-About the Same, 5-A Little Worse, 6-Moderately Worse, 7-Much Worse. | Up to 5 years |
| Change in score of the FACT-G GP5 item in the patient population | Part 2 A single item GP5 of the validated FACT-G questionnaire will be used to assess from the participant perspective the overall impact of treatment side-effect. The question item is on a 5-point scale ranging from "not at all" (0) to "very much" (4). | Up to 5 years |
| Noblesville |
| Indiana |
| 46062 |
| United States |
| Cancer Center of Kansas | Wichita | Kansas | 67214 | United States |
| University of Kentucky | Lexington | Kentucky | 40536 | United States |
| Henry Ford Health System | Detroit | Michigan | 48202 | United States |
| Cancer and Hematology Centers of Western Michigan | Grand Rapids | Michigan | 49503 | United States |
| Center for Oncology and Blood Disorders | Houston | Texas | 77030 | United States |
| Community Cancer Trials of Utah | Ogden | Utah | 84405 | United States |
| Prohealth Care Inc | Waukesha | Wisconsin | 53188 | United States |
| Liverpool Hospital | Liverpool | New South Wales | 2170 | Australia |
| Calvary Mater Newcastle | Waratah | New South Wales | 2298 | Australia |
| Pindara Private Hospital | Benowa | Queensland | 4217 | Australia |
| Karl Landsteiner University Hospital St. Poelten | Sankt Pölten | Lower Austria | 3100 | Austria |
| Medical University of Graz | Graz | Styria | 8036 | Austria |
| Landeskrankenhaus Hochsteiermark | Leoben | Styria | 8700 | Austria |
| Innsbruck Medical University | Innsbruck | Tyrol | 6020 | Austria |
| Kepler University Hospital | Linz | Upper Austria | 4020 | Austria |
| Universitatsklinik fur Kinder und Jungendheilkunde | Vienna | 1090 | Austria |
| Klinikum Wels-Grieskirchen | Wels | 4600 | Austria |
| Universitair Ziekenhuis (UZ) Gent/ Ghent University Hospital | Ghent | Oost-Vlaanderen | 9000 | Belgium |
| Verenigde Ziekenhuizen van Waas en Durme | Sint-Niklaas | Oost-Vlaanderen | 9100 | Belgium |
| Algemeen Ziekenhuis St Jan Brugge Oostende Av | Bruges | West-Vlaanderen | 8000 | Belgium |
| AZ Groeninge | Kortrijk | West-Vlaanderen | 8500 | Belgium |
| Institut Jules Bordet | Brussels | 1000 | Belgium |
| Centre Hospitalier Regional de la Citadelle | Liège | 4000 | Belgium |
| Hospital Santa Izabel - Santa Casa de Misericordia da Bahia | Salvador | Estado de Bahia | 40050-410 | Brazil |
| Hospital Sao Rafael | Salvador | Estado de Bahia | 41253-900 | Brazil |
| Ensino e Terapia de Inovacao Clinica Amo (Etica) | Salvador | Estado de Bahia | 41950-640 | Brazil |
| Hospital Sirio Libanes Brasilia | Brasília | Federal District | 70200-730 | Brazil |
| Instituto DOr de Pesquisa e Ensino Df Star | Brasília | Federal District | 70390-140 | Brazil |
| Instituto Mario Pena de Ensino Pesquisa e Inovacao | Belo Horizonte | Minas Gerais | 30380-472 | Brazil |
| Centro Oncologico do Triangulo (COT) - Uberlandia | Uberlândia | Minas Gerais | 38408-008 | Brazil |
| Hospital Erasto Gaertner | Curitiba | Paraná | 81520-060 | Brazil |
| Liga Norte Riograndense Contra o Cancer | Natal | Rio Grande do Norte | 59062-000 | Brazil |
| Instituto Tacchini de Pesquisa em Saude | Bento Gonçalves | Rio Grande do Sul | 95700-084 | Brazil |
| Instituto do Cancer em Hospital Sao Vicente de Paulo | Passo Fundo | Rio Grande do Sul | 99010-080 | Brazil |
| Hospital de Clinicas de Porto Alegre | Porto Alegre | Rio Grande do Sul | 90035-903 | Brazil |
| Centro de Hematologia e Oncologia | Joinville | Santa Catarina | 89201-260 | Brazil |
| Animi Unidade de Tratamento Oncologico Ltda | Lages | Santa Catarina | 88501-001 | Brazil |
| Fundacao Pio XII Hospital de Amor | Barretos | São Paulo | 14784-400 | Brazil |
| Amaral Carvalho Hospital | Jaú | São Paulo | 17210-080 | Brazil |
| Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto | Ribeirão Preto | São Paulo | 14048-900 | Brazil |
| Instituto Nacional de Cancer Jose Alencar Gomes da Silva | Rio de Janeiro | 20231050 | Brazil |
| Hospital Alemao Oswaldo Cruz | São Paulo | 01323-903 | Brazil |
| AC Camargo Cancer Center | São Paulo | 01509-010 | Brazil |
| Clinical Hospital of Medicine School at Sao Paulo University | São Paulo | 05403-000 | Brazil |
| Casa de Saude Santa Marcelina | São Paulo | 08270-070 | Brazil |
| Hospital Clinico Universidad de Los Andes | Santiago | Las Condes | 7620157 | Chile |
| Pontificia Universidad Catolica de Chile | Santiago | Santiago Metropolitan | 7550000 | Chile |
| Centro Oncologia de Precision Universidad Mayor | Santiago | Santiago Metropolitan | 7560907 | Chile |
| Inmunocel | Santiago | Santiago Metropolitan | 7580206 | Chile |
| University Hospital Hradec Kralove | Hradec Králové | North Central Czech Republic | 50005 | Czechia |
| University Hospital Brno | Brno | South Moravian | 62500 | Czechia |
| Cannes Hospital (Centre Hospitalier Cannes Simone Veil) | Cannes | Alpes Maritimes | 06400 | France |
| CHRU de Tours | Tours | Centre-Val de Loire | 37044 | France |
| Institut de Cancerologie du Gard | Nîmes | Gard | 30029 | France |
| Centre Hospitalier de Mont-de-Marsan | Mont-de-Marsan | New Aquitaine | 40024 | France |
| Nantes University Hospital | Nantes | Pays de la Loire Region | 44093 | France |
| The Novo Hospital North West Val Deoise | Cergy-Pontoise | Pontoise | 95300 | France |
| Centre Hospitalier Universitaire de Grenoble | Grenoble | 38043 | France |
| Centre Hospitalier Emile Roux | Le Puy-en-Velay | 43012 | France |
| Centre Hospitalier de Lens (Centre Hospitalier Dr Schaffner dLens) | Lens | 62300 | France |
| Hopital Saint Louis | Paris | 75010 | France |
| Centre Hospitalier Universitaire de Bordeaux - Groupe Hospitalier Sud - Hôpital Haut Lévêque | Pessac | 33600 | France |
| CHU de Saint-Etienne | Saint-Etienne | 42055 | France |
| Centre Hospitalier de Saint Nazaire | Saint-Nazaire | 44600 | France |
| Hopital Victor Dupouy Argenteuil | Argenteuil | Île-de-France Region | 95100 | France |
| Stadtisches Krankenhaus Kiel | Kiel | 24116 | Germany |
| MVZ fuer Haematologie und Onkologie Rhein-Kreis GmbH | Neuss | 41462 | Germany |
| Shaare Zedek Medical Center | Jerusalem | Jerusalem | 9103102 | Israel |
| Soroka University Medical Center | Beersheba | 84101 | Israel |
| Rambam Health Care Campus | Haifa | 3109601 | Israel |
| Hadassah Medical Center | Jerusalem | 91200 | Israel |
| Rabin Medical Center | Petah Tikva | 49100 | Israel |
| The Tel Aviv Sourasky Medical Center | Tel Aviv | 64239 | Israel |
| Assuta Medical Centers | Tel Aviv | 6971028 | Israel |
| Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori | Meldola | Forli-Cesena | 47014 | Italy |
| Azienda Ospedaliera Ordine Mauriziano Torino, Presidio Umberto I of Turin | Turin | Piedmont | 10137 | Italy |
| Azienda Ospedaliera Universitario Policlinico Palermo | Palermo | Sicily | 90127 | Italy |
| ASST Grande Ospedale Metropolitano Niguarda - Main Address | Milan | 20162 | Italy |
| Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico | Milan | 20122 | Italy |
| Istituto Europeo di Oncologia | Milan | 20141 | Italy |
| A.O.U. di Modena | Modena | 41124 | Italy |
| Federico II University | Naples | 80131 | Italy |
| Azienda Ospedaliera di Perugia | Perugia | 06132 | Italy |
| University of Pisa, Section of Hematology | Pisa | 56126 | Italy |
| Azienda Ospedaliera Regionale San Carlo | Potenza | 85100 | Italy |
| UO Ematologia Ravenna | Ravenna | 48121 | Italy |
| Azienda Unita Sanitaria Locale Irccs Arcispedale Santa Maria Nuova | Reggio Emilia | 42123 | Italy |
| Azienda Osperdaliero-Universitaria Policlinico Umberto 1 | Rome | 00161 | Italy |
| Azienda Sanitaria Universitaria del Friuli Centrale | Udine | 33100 | Italy |
| Matopolskie Centrum Medyczne S.C. | Krakow | Lesser Poland Voivodeship | 30-510 | Poland |
| Aidport | Skorzewo | Wielkopolska | 60185 | Poland |
| Szpital Uniwersytecki Nr2 Bydgoszcz | Bydgoszcz | 85-168 | Poland |
| Uniwersyteckie Centrum Kliniczne, Building of the Non-Invasive Medicine Center | Gdansk | 80-952 | Poland |
| Pratia Onkologia Katowice | Katowice | 40-519 | Poland |
| Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. Mikolaja Kopernika w Lodzi (Copernicus Memorial Hospital) | Lodz | 93-513 | Poland |
| Centrum Innowacyjnych Terapii Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie | Lublin | 20-954 | Poland |
| Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy Warszawa | Warsaw | 02781 | Poland |
| Szpital Szpecjalistyczny w Walbrzychu | Wałbrzych | 58-300 | Poland |
| Hospital Universitario Virgen del Rocio | Seville | Andalusia | 41013 | Spain |
| Parc Tauli Sabadell Hospital Universitari | Sabadell | Barcelona | 08208 | Spain |
| Hospital Universitari Mutua Terrassa | Terrassa | Barcelona | 08221 | Spain |
| Cruces University Hospital (Hospital Universitario Cruces) | Barakaldo | Bizkaia | 48903 | Spain |
| Hospital Universitario Puerta de Hierro - Majadahonda | Majadahonda | Madrid | 28222 | Spain |
| Hospital Universitario Quiron Salud Madrid | Pozuelo de Alarcón | Madrid | 28223 | Spain |
| Hospital Universitario de Navarra | Pamplona | Navarre | 31008 | Spain |
| Hospital Universitario Central de Asturias | Oviedo | Principality of Asturias | 33011 | Spain |
| Hospital General Universitario Doctor Balmis Alicante | Alicante | Valencia | 03010 | Spain |
| Hospital Universitario Lucus Augusti | Lugo | 27003 | Spain |
| Clinica Universidad de Navarra - Madrid | Madrid | 28027 | Spain |
| Hospital Universitario Infanta Leonor | Madrid | 28031 | Spain |
| Hospital Universitario Ramon y Cajal | Madrid | 28034 | Spain |
| Hospital Universitario Fundacion Jimenez Diaz | Madrid | 28040 | Spain |
| Hospital Universitario 12 de Octubre | Madrid | 28041 | Spain |
| Complexo Hospitalario Universitario de Ourense | Ourense | 32005 | Spain |
| Clinica Universidad de Navarra- Pamplona | Pamplona | 31008 | Spain |
| Hospital Universitario de Salamanca | Salamanca | 37007 | Spain |
| Hospital Universitario Virgen Macarena | Seville | 41009 | Spain |
| Instituto Valenciano de Oncologia | Valencia | 46009 | Spain |
| Hospital Clinico Universitario de Valencia | Valencia | 46010 | Spain |
| Kaohsiung Medical University Hospital | Kaohsiung City | 80756 | Taiwan |
| Chang Gung Memorial Hospital Kaohsiung | Kaohsiung City | 83301 | Taiwan |
| Taipei Medical University - Shuang Ho Hospital | New Taipei City | 23561 | Taiwan |
| Taipei Veterans General Hospital | Taipei | 11217 | Taiwan |
| Tri-Service General Hospital | Taipei | 11490 | Taiwan |
| Taipei Medical University Multipal Wan Fang University | Taipei | 11696 | Taiwan |
| Chulalongkorn University | Bangkok | Krung Thep Maha Nakhon [Bangko] | 10330 | Thailand |
| Khon Kaen University | Khon Kaen | 40002 | Thailand |
| Ankara University Faculty of Medicine | Mamak | Ankara | 06620 | Turkey (Türkiye) |
| Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital | Yenimahalle | Ankara | 06200 | Turkey (Türkiye) |
| Gazi University | Ankara | Central Anatolia | 06100 | Turkey (Türkiye) |
| VM Medical Park Mersin Hospital | Mezitli | Mersin | 33200 | Turkey (Türkiye) |
| Sakarya University | Sakarya | Serdivan | 54050 | Turkey (Türkiye) |
| Tekirdag Namik Kemal University Hospital | Tekirdağ | Suleymanpasa | 59100 | Turkey (Türkiye) |
| Liv Hospital Ankara | Ankara | 06100 | Turkey (Türkiye) |
| VKV American Hopital | Istanbul | 34365 | Turkey (Türkiye) |
| Istanbul University | Istanbul | 34418 | Turkey (Türkiye) |
| Erci̇yes Uni̇versi̇ty | Kayseri | 38039 | Turkey (Türkiye) |
| Ondokuz Mayıs University | Samsun | 55270 | Turkey (Türkiye) |
| Zonguldak Bulent Ecevit University | Zonguldak | 67100 | Turkey (Türkiye) |
| Royal Cornwall Hospital | Truro | Cornwall | TR1 3LJ | United Kingdom |
| The Hillingdon Hospitals NHS Foundation Trust | Uxbridge | London | UB8 3NN | United Kingdom |
| University Hospitals Birmingham NHS Foundation Trust | Birmingham | West Midlands | B15 2SY | United Kingdom |
| NHS Grampian: Aberdeen Royal Infirmary | Aberdeen | AB25 2ZN | United Kingdom |
| ID | Term |
|---|---|
| D008224 | Lymphoma, Follicular |
| D012008 | Recurrence |
| ID | Term |
|---|---|
| D008228 | Lymphoma, Non-Hodgkin |
| D008223 | Lymphoma |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069283 | Rituximab |
| D003520 | Cyclophosphamide |
| D004317 | Doxorubicin |
| D014750 | Vincristine |
| D011241 | Prednisone |
| D008775 | Methylprednisolone |
| ID | Term |
|---|---|
| D058846 | Antibodies, Monoclonal, Murine-Derived |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
| D010752 | Phosphoramide Mustards |
| D009588 | Nitrogen Mustard Compounds |
| D009150 | Mustard Compounds |
| D006846 | Hydrocarbons, Halogenated |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D063088 | Phosphoramides |
| D009943 | Organophosphorus Compounds |
| D003630 | Daunorubicin |
| D018943 | Anthracyclines |
| D009279 | Naphthacenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D011083 | Polycyclic Compounds |
| D000617 | Aminoglycosides |
| D006027 | Glycosides |
| D002241 | Carbohydrates |
| D014748 | Vinca Alkaloids |
| D046948 | Secologanin Tryptamine Alkaloids |
| D026121 | Indole Alkaloids |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
| D007211 | Indoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D054836 | Indolizidines |
| D007212 | Indolizines |
| D011244 | Pregnadienediols |
| D011245 | Pregnadienes |
| D011278 | Pregnanes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011239 | Prednisolone |
| D011246 | Pregnadienetriols |
Not provided
Not provided